Eli Lilly presented compelling clinical evidence positioning its BTK inhibitor Jaypirca as a potentially superior treatment option compared to the established blood cancer therapy Imbruvica, marking a significant competitive shift…
The most common form of leukemia in Western countries is chronic lymphocytic leukemia (CLL). The disease accounts for almost thirty percent of known leukemia cases. Approximately 30,000 Europeans were…
Roger Bliss, 68-year-old pulmonary hypertension (PH) patient, was diagnosed with chronic lymphocytic leukemia and small lymphocytic lymphoma. In addition, Roger has celiac disease. He recently interviewed with Pulmonary Hypertension News.…
Targeted Oncology recently featured a discussion by Dr. Jennifer Brown, director of Dana Farber’s Chronic Lymphocytic Leukemia Center, on the interim results from the SEQUOIA Phase 3 trial. The trial…
The 2021 Society for Hematological Oncology (SOHO) Annual Meeting took place last month from September 8-11, 2021. During the meeting, researchers discussed new advances in the field of hematology. According…
Meghan Thompson, a doctor and 3rd year fellow at Memorial Sloan Kettering Cancer Center has recently explained all of the emerging treatments using BTK inhibitors to treat CLL, chronic lymphocytic…
A recent case study published in The Journal of Cancer Research and Oncobiology is believed to have recorded the first case of lactic acidosis in a patient with small lymphocytic…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
